Teva Pharmaceutical Industries Limited (TEVA)
Filed: 22 Apr 20, 7:57am
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
SCHEDULE 14A
Proxy Statement Pursuant to Section 14(a) of
the Securities Exchange Act of 1934
Filed by the Registrant ☒
Filed by a Party other than the Registrant ☐
Check the appropriate box:
| ☐ | Preliminary Proxy Statement | ☐ | Confidential, For Use of the Commission Only (as permitted by Rule14a-6(e)(2)) | |||
| ☐ | Definitive Proxy Statement | |||||
| ☒ | Definitive Additional Materials | |||||
| ☐ | Soliciting Material under§240.14a-12 |
TEVA PHARMACEUTICAL INDUSTRIES LIMITED
(Name of Registrant as Specified In Its Charter)
(Name of Person(s) Filing Proxy Statement, if other than the Registrant)
Payment of Filing Fee (Check the appropriate box):
| ☒ | No fee required. | |||
| ☐ | Fee computed on table below per Exchange Act Rules14a-6(i) (1) and0-11. | |||
| (1) | Title of each class of securities to which transaction applies: | |||
| ||||
| (2) | Aggregate number of securities to which transaction applies: | |||
| ||||
| (3) | Per unit price or other underlying value of transaction computed pursuant to Exchange Act Rule0-11 (set forth the amount on which the filing fee is calculated and state how it was determined): | |||
| ||||
| (4) | Proposed maximum aggregate value of transaction: | |||
| ||||
| (5) | Total fee paid: | |||
| ||||
| ☐ | Fee paid previously with preliminary materials. | |||
| ☐ | Check box if any part of the fee is offset as provided by Exchange Act Rule0-11(a)(2) and identify the filing for which the offsetting fee was paid previously. Identify the previous filing by registration statement number, or the Form or Schedule and the date of its filing. | |||
| (1) | Amount Previously Paid: | |||
| ||||
| (2) | Form, Schedule or Registration Statement No.: | |||
| ||||
| (3) | Filing Party: | |||
| ||||
| (4) | Date Filed: | |||
| ||||
The following communication was sent to certain beneficial holders of its American Depositary Shares by or on behalf of Teva Pharmaceutical Industries Limited:
*** Exercise Your Right to Vote *** Important Notice Regarding the Availability of Proxy Materials for the Shareholder Meeting to Be Held on <mtgdate> June 09, 2020 . Meeting Information TEVA PHARMACEUTICAL INDUSTRIES LIMITED Meeting Type: Annual <mtgtype> Meeting For holders as of: April <recdate> 09, 2020 B Date: June 09, 2020 Time: 4:30 <mtgtime> PM LST A Location: 5 Basel Street, R Petach Tikva, 4951033 Israel C BROKER LOGO O HERE D E You are receiving this communication because you hold Return Address Line 1 shares in the above named company. Return Address Line 2 Return Address Line 3 51 MERCEDES WAY This is not a ballot. You cannot use this notice to vote EDGEWOOD NY 11717 these shares. This communication presents only an Investor Address Line 1 overview of the more complete proxy materials that are Investor Address Line 2 1 available to you on the Internet. You may view the proxy Investor Address Line 3 materials online at www.proxyvote.com or easily request a 18 Investor Address Line 4 15 12 OF paper copy (see reverse side). 1 . . 0 Investor Address Line 5 . R1 John Sample 2 We encourage you to access and review all of the important 1234 ANYWHERE STREET information contained in the proxy materials before voting. 1 ANY CITY, ON A1A 1A1 _ See the reverse side of this notice to obtain proxy materials and voting instructions. 0000463676 Broadridge Internal Use Only Job # Envelope # Sequence # # of # Sequence #
Before You Vote How to Access the Proxy Materials Proxy Materials Available to VIEW or RECEIVE: 1. Proxy Statement 2. Annual Report How to View Online: Have the information that is printed in the box marked by the arrow (located on the following page) and visit: www.proxyvote.com. How to Request and Receive a PAPER orE-MAIL Copy: If you want to receive a paper ore-mail copy of these documents, you must request one. There is NO charge for requesting a copy. Please choose one of the following methods to make your request: 1) BY INTERNET: www.proxyvote.com 2) BY TELEPHONE:1-800-579-1639 3) BYE-MAIL*: sendmaterial@proxyvote.com * If requesting materials bye-mail, please send a blanke-mail with the information that is printed in the box marked by the arrow (located on the following page) in the subject line. Requests, instructions and other inquiries sent to thise-mail address will NOT be forwarded to your investment advisor. Please make the request as instructed above on or before May 22, 2020 to facilitate timely delivery. How To Vote Please Choose One of the Following Voting Methods . 18 . 1 Vote In Person: If you choose to vote these shares in person at the meeting, you must request a “legal proxy.” To do . 0 so, please follow the instructions at www.proxyvote.com or request a paper copy of the materials, which will contain the R1 appropriate instructions. Many shareholder meetings have attendance requirements including, but not limited to, the _ 2 possession of an attendance ticket issued by the entity holding the meeting. Please check the meeting materials for any special requirements for meeting attendance. 0000463676 Vote By Internet: To vote now by Internet, go to www.proxyvote.com. Have the information that is printed in the box marked by the arrow available and follow the instructions. Internal Use Only Vote By Mail: You can vote by mail by requesting a paper copy of the materials, which will include a voting instruction form.
Voting items The Board of Directors recommends you vote FOR the following proposal(s): 1. Election of Directors 6 To appoint Kesselman & Kesselman, a Nominees member of PricewaterhouseCoopers International Ltd., as Teva’s 1A Dr. Sol J. Barer independent registered public accounting firm until Teva’s 2021 B annual meeting of shareholders. 1B Jean-Michel Halfon A R 1C Nechemia (Chemi) Peres C 1D Janet S. Vergis O D The Board of Directors recommends you vote FOR the following E proposal(s): 2 To approve, on anon-binding advisory basis, the compensation for Teva’s named executive officers. 3 To approve Teva’s 2020 Long-Term Equity-Based Incentive Plan, substantially in the form attached 18 as Appendix A to the Proxy 1 . Statement. 0 . R1 . 4 To approve an amendment to the terms of office and employment of 3 _ Teva’s President and Chief Executive Officer. Broadridge Internal Use Only 5 To approve an amendment to Teva’s xxxxxxxxxx 0000463676 xxxxxxxxxx Articles of Association. Cusip Job # Envelope # Sequence # # of # Sequence #
Voting items Continued Reserved for Broadridge Internal Control Information NOTE: **In order for your ADS votes to be counted, you must be an ADS holder as of Apr 30, 2020. In addition, shareholders will consider Teva’s annual consolidated financial statements for the year ended December 31, 2019. Voting Instructions THIS SPACE RESERVED FOR LANGUAGE PERTAINING TO BANKS AND BROKERS 18 . AS REQUIRED BY THE NEW YORK STOCK EXCHANGE . 1 . 0 R1 _ 4 0000463676 Broadridge Internal Use OnlyP99999-010 12 Job # THIS SPACE RESERVED FOR SIGNATURES IF APPLICABLE Envelope # Sequence 15 # # of # Sequence # OF##
The following communication was sent to certain registered holders of its American Depositary Shares by or on behalf of Teva Pharmaceutical Industries Limited:
+ Teva Pharmaceutical C 1234567890 Industries Limited 000004 ENDORSEMENT_LINE SACKPACK MR A SAMPLE Online DESIGNATION (IF ANY) ADD 1 Go to www.investorvote.com/teva or scan the ADD 2 QR code — login details are located in the ADD 3 shaded bar below. ADD 4 ADD 5 ADD 6 Votes submitted electronically must be received by 8 a.m., Eastern Time, on June 8, 2020. Teva Pharmaceutical Industries Limited Shareholder Meeting Notice 1234 5678 9012 345 Important Notice Regarding the Availability of Proxy Materials for the Shareholder Meeting to be Held on June 9, 2020 Under Securities and Exchange Commission rules, you are receiving this notice that the proxy materials for the annual shareholders’ meeting are available on the Internet. Follow the instructions below to view the materials and vote online or request a copy. The items to be voted on and location of the annual meeting are on the reverse side. Your vote is important! This communication presents only an overview of the more complete proxy materials that are available to you on the Internet. We encourage you to access and review all of the important information contained in the proxy materials before voting. The proxy statement and annual report to shareholders are available at: www.investorvote.com/teva Easy Online Access — View your proxy materials and vote. Step 1: Go to www.investorvote.com/teva. Step 2: Click on the icon on the right to view meeting materials. Step 3: Return to the investorvote.com window and follow the instructions on the screen to log in. Step 4: Make your selections as instructed on each screen for your delivery preferences. Step 5: Vote your shares. When you go online, you can also help the environment by consenting to receive electronic delivery of future materials. Obtaining a copy of the Proxy Materials – If you want to receive a copy of the proxy materials, you must request one. There is no charge to you for requesting a copy. Please make your request as instructed on the reverse side on or before May 22, 2020 to facilitate timely delivery. 2NOT COY + 038I6D
Shareholder Meeting Notice Teva Pharmaceutical Industries Limited’s Annual Meeting of Shareholders will be held on June 9, 2020 at Teva’s executive offices at 5 Basel Street, Petach Tikva, 4951033 Israel, at 4:30 p.m. (local time). Proposals to be voted on at the meeting are listed below along with the Board of Director’s recommendations. Teva’s Board of Directors recommends that you vote FOR all proposals: 1. Election of Directors a. Dr. Sol J. Barer b. Jean-Michel Halfon c. Nechemia (Chemi) J. Peres d. Janet S. Vergis 2. To approve, on anon-binding advisory basis, the compensation for Teva’s named executive officers. 3. To approve Teva’s 2020 Long-Term Equity-Based Incentive Plan, substantially in the form attached as Appendix A to the Proxy Statement. 4. To approve an amendment to the terms of office and employment of Teva’s President and Chief Executive Officer. 5. To approve an amendment to Teva’s Articles of Association. 6. To appoint Kesselman & Kesselman, a member of PricewaterhouseCoopers International Ltd., as Teva’s independent registered public accounting firm until Teva’s 2021 annual meeting of shareholders. In addition, shareholders will consider Teva’s annual consolidated financial statements for the year ended December 31, 2019. PLEASE NOTE – YOU CANNOT VOTE BY RETURNING THIS NOTICE. To vote your shares you must go online or request a paper copy of the proxy materials to receive a proxy card. If you wish to attend the meeting, please bring this notice with you. If you wish to vote at the shareholder meeting, you must present your Teva ADSs for cancellation and withdrawal of the corresponding Teva ordinary shares in time to be a shareholder of Teva as of April 30, 2020 (i.e. the record date for the shareholder meeting). Information on how to obtain directions to the Teva Pharmaceutical Industries Limited shareholder meeting is available in the proxy statement available at www.investorvote.com/teva. PLEASE NOTE: In order for your ADS votes to be counted, you must be an ADS holder as of April 30, 2020 . Here’s how to order a copy of the proxy materials and select delivery preferences: Current and future delivery requests can be submitted using the options below. If you request an email copy, you will receive an email with a link to the current meeting materials. PLEASE NOTE: You must use the number in the shaded bar on the reverse side when requesting a copy of the proxy materials. — Internet – Go to www.investorvote.com/teva. — Phone – Call us free of charge at1-866-641-4276. — Email – Send an email to investorvote@computershare.com with “Proxy Materials Teva Pharmaceutical Industries Limited” in the subject line. Include your full name and address, plus the number located in the shaded bar on the reverse side, and state that you want a paper copy of the meeting materials. To facilitate timely delivery, requests for a paper copy of proxy materials must be received by May 22, 2020
The following communication was sent to certain holders of its ordinary shares by Teva Pharmaceutical Industries Limited:
| TEVA PHARMACEUTICAL INDUSTRIES LIMITED | ||
 | 2020 ANNUAL MEETING OF SHAREHOLDERS June 9, 2020 4:30 p.m. (Israel time) Teva’s executive offices 5 Basel Street Petach Tikva, 4951033 Israel | |
Directions to the Teva Pharmaceutical Industries Limited 2020 Annual Meeting of Shareholders and information on how to vote in person are available in the proxy statement which can be viewed at www.tevapharm.com/2020proxymaterials. | ||
Important Notice Regarding the Availability of Proxy Materials for the
Shareholder Meeting to be Held on June 9, 2020.
Notice is hereby given that the 2020 Annual Meeting of Shareholders (the “meeting”) of Teva Pharmaceutical Industries Limited (“Teva”) will be held at 5 Basel Street, Petach Tikva, 4951033 Israel on June 9, 2020 at 4:30 p.m. (Israel time).
This communication presents only an overview of the more complete proxy materials that are available to you on the Internet. We encourage you to access and review all of the important information contained in the proxy materials before voting. This is not a form for voting.
The Proxy Statement and Annual Report are available at www.tevapharm.com/2020proxymaterials.
If you want to receive a paper copy or ane-mail with links to the electronic materials, you must request one. There is no charge to you for requesting a copy. Please make your request for a copy as instructed below on or before May 22, 2020 to facilitate timely delivery.
Matters intended to be acted upon at the meeting are listed below.
| 1. | To appoint the following persons: Dr. Sol J. Barer, Jean-Michel Halfon, Nechemia (Chemi) J. Peres and Janet S. Vergis to serve on the Board of Directors until our 2023 annual meeting of shareholders. |
| 2. | To approve, on anon-binding advisory basis, the compensation for Teva’s named executive officers. |
| 3. | To approve Teva’s 2020 Long-Term Equity-Based Incentive Plan, substantially in the form attached as Appendix A to the Proxy Statement. |
| 4. | To approve an amendment to the terms of office and employment of Teva’s President and Chief Executive Officer. |
| 5. | To approve an amendment to Teva’s Articles of Association. |
| 6. | To appoint Kesselman & Kesselman, a member of PricewaterhouseCoopers International Ltd., as Teva’s independent registered public accounting firm until Teva’s 2021 annual meeting of shareholders. |
In addition, shareholders will consider Teva’s annual consolidated financial statements for the year ended December 31, 2019.
The Board of Directors recommends that you vote FOR all proposals.
To request paper copies of the proxy materials, which include the proxy card,
proxy statement and annual report, please contact us via:
| • | Telephone – Call our proxy solicitor, MacKenzie Partners, Inc., toll free within the U.S. at +1 (800)322-2885 or outside the U.S. at + 1 (212)929-5500. In Israel, call us at +972 (3)926-7516. |
| • | Email – Send us an email at TevaIR@tevapharm.com or send an email to our proxy solicitor, MacKenzie Partners, Inc., at proxy@mackenziepartners.com, with “Teva Materials Request” in the subject line. The email must include: |
| • | Your preference to receive printed materials via mail-or- to receive an email with links to the electronic materials. |
| • | If you choose email delivery you must include the email address. |
| • | If you would like this election to apply to delivery of material for all future meetings, write the word “Permanent”. |
In order to ensure timely delivery, you must request the information no later than May 22, 2020.
2